Young researchers working in Europe are invited to apply for the Eppendorf Award for Young European Investigators.
Researchers who are less than 35 have until 15 January 2012 to apply.
The award, inaugurated in 1995, acknowledges outstanding contributions to biomedical research in Europe based on methods of molecular biology, including novel analytical concepts.
An independent expert committee chaired by Kai Simons of the Max Planck Institute for Molecular Cell Biology and Genetics, in Dresden, Germany, will choose the winner.
The successful entrant will receive €15,000 in prize money and an invitation to the prize-giving ceremony at the EMBL Advanced Training Centre in Heidelberg, Germany on 9 May 2012.
In addition, he/she will be invited to Eppendorf in Hamburg and coverage of his/her work will be published in Nature magazine and in a podcast.
The official registration portal is at www.eppendorf.com/award/application. Only online registrations will be accepted.
Full details on the Eppendorf Award, the selection criteria and past award winners, are available at www.eppendorf.com/award.
Eppendorf Award for Young European Investigators opens for entry
Deadline is 15 January 2012
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Research & Development
The path to commercial allogeneic iPSC therapies
The cell therapy sector is currently shifting from patient-specific autologous treatments toward off-the-shelf allogeneic cell therapies. Although this transition is helping to democratise access to treatments, it introduces several challenges in terms of controlling complex biology at a commercial scale
Research & Development
The IND advantage: why early derisking is a strategic imperative for complex biologics
As biologics grow more complex, early identification and the mitigation of manufacturability, stability and immunogenicity risks have become the critical factor separating programmes that reach IND on time from those that don't, says Yvette Stallwood, Head of Early Development Services at Lonza
Research & Development
Stipple Bio enters into multi-target license agreement with Lonza to advance precision oncology ADC therapies
Stipple Bio’s Pointillist Platform identifies tumour-specific cell surface epitopes that, when combined with Lonza’s clinically validated ADC platform, may enable first-in-class and best-in-class ADC oncology medicines such as STP-100
Research & Development
Lonza advances integrated DNA‑to‑IND programmes with acceleration, derisking and innovation
New GS Ori‑Go vector technology supports titers higher than 11 g/L and reliable bulk pool stability, enabling more predictable material generation and shortened cell line development timelines